PHASE 2 STUDY OF ALISERTIB AS A SINGLE AGENT IN RECURRENT OR PROGRESSIVE CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID RHABDOID TUMORS (AT/RT) AND EXTRA-CNS MALIGNANT RHABDOID TUMORS (MRT) AND IN COMBINATION THERAPY IN NEWLY DIAGNOSED AT/RT (SJATRT)
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Kathleen Dorris, MD
Study ID
Protocol Number: 15-1302
More information available at ClinicalTrials.gov: NCT02114229
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers